Development Associate

Khalid Benbatoul

**** ****** ***** ****, ** Jolla, CA 92037

Home: 858-***-****

Cell: 858-***-****

******@*********.***

QUALIFICATIONS SUMMARY

A goal and quality driven scientist with demonstrated dedication and enthusiasm in the Research and

Development arena within the Pharmaceutical/Biotechnology industry. Broad and diverse experience

in Molecular and Cellular Biology with a wide range of skills in areas of Drug Discovery and Assay

Development at both the in-vitro and in-vivo levels. Good knowledge of Drug Discovery process

from the pre-clinical to post-clinical stages. Demonstrated keen ability and flexibility to adapt to new

technologies and ideas while delivering results. Exceptional team player with excellent rapport with

colleagues and collaborators. Excellent oral and written communication skills with ability to present

data in effective and concise manner.

EDUCATION

Pre-medical-B.S., Molecular/Cell Biology, Sociology.

University Of California San Diego (UCSD) 1989-1993

Relevant coursework:

Biochemistry, Organic Chemistry, Immunology, Medical Microbiology, Bacteriology, Endocrinology,

Mammalian Physiology, Genetics, Molecular Basis of Disease, Basic Computer Programming.

WORK EXPERIENCE

Vaxiion Therapeutics.

San Diego, Ca.

Senior Research Associate December. 2010- Oct.2012

* Development, optimization, and validation of cell based assays to assess the in-vitro anti-tumor

activity using Vaxiion’s protein toxin loaded minicells.

Biogen Idec.

Translational Bio-Oncology Group

San Diego, Ca.

Senior Associate Scientist May 2010- December 2010

* Profiling and characterization of lead protein constructs and elucidation on their mechanism of

action (MOA) regarding their activities in apoptosis and modulation of cell survival signaling

pathways in primary human tumor cells and multiple cancer cell lines.

Tanabe Research Laboratories U.S.A.

San Diego, Ca.

Senior Research Associate August 2007- February 2010

* Development and establishment of an ex-vivo isolation and differentiation assay for human and

mouse Th17 cells.

* Flow Cytometry analysis of Orphan Nuclear Receptor inhibitors for the differentiation of various

T-cell populations including, Th17 and T-regulatory cells.

* Development of biochemical assay to screen and profile enzyme inhibitors for various targets

within the Glucose-Insulin pathways.

Ligand Pharmaceuticals Inc.

San Diego, Ca.

Associate Scientist July 2002- February 2007

* Development and validation of quantitative real time PCR assays to predict the effects of Selective

Glucocorticoid Receptor Modulators (SGRM) on the hypothalamic pituitary-adrenal axis (HPA),

and Skeletal Muscles.

* Investigation and establishment of clinical Biomarkers to assess the efficacy of the SGRM clinical

candidate compounds.

* Mutational analysis of Glucocorticoid Receptor and its interactions with steroidal and non-

steroidal ligands.

* Gene expression analysis of steroidal and non-steroidal compounds in the SGRM program.

* Investigation and development of inflammatory and bone Biomarkers for the assessment of the

effects of non-steroidal Glucocorticoid Receptor Modulators in the Adjuvant Induced Arthritis

(AIA) rat model, and Collagen Induced Arthritis (CIA) mouse model.

Bristol Myers-Squibb Research Institute.

Princeton, NJ.

Associate Research Scientist July 2000- July 2002

* Development and establishment of in-vitro Biomarkers for the evaluation of CDK2 inhibitors.

* Evaluation of the Beta-Lactamase as a reliable reporter assay for the screening of p53 modulator

compounds.

* Characterization and screen of Proteasome inhibitors as potential target for cancer therapy.

* Development of the Golden Syrian Hamster as a potential model for the reversal of Chemotherapy

induced Alopecia.

Ligand Pharmaceuticals Inc.

San Diego, Ca.

Assistant Scientist August 1998- June 2000

* Characterization and assessment of non-steroidal anti-androgen compounds on the growth of the

Golden Syrian Hamster’s flank organ hair-a Histomorphometric Bio-imaging analysis.

* In-vivo characterization of non-steroidal Selective Androgen Modulators (SARM) compounds.

* Development and establishment of an adenovirus based assay for the expression of Androgen

Receptor in human skeletal muscle.

Ontogen Corporation.

Carlsbad, Ca.

Research Associate February 1997- August 1998

* In –vitro characterization of P-glycoprotein (P-gp) associated Multi-Drug Resistance (MDR)

modulators.

UCSD School of Medicine, Cancer Center, Dept. of Medicine.

La Jolla, Ca.

Staff Research Associate September 1996- February 1997

* Determination of the role of DAL-1 in lung cancer and its significance as a marker in

Tunerigenesis

UCSD School of Medicine, Cancer Center, Division of Otolaryngology-

Head and Neck Surgery, Dept. of Surgery

Clayton Foundation for Research

La Jolla, Ca.

Staff Research Associate June 1994- July 1995

* Quantitative assessment of tumor sensitivity to anti-cancer drugs

UCSD School of Medicine, Division of Infectious Diseases,

Dept. of Pediatrics.

La Jolla, Ca.

Staff Research Associate February 1991- May 1994

* Molecular characterization of Foscarnet resistant phenotype of viral isolates from Human

Cytomegalovirus (HCMV)

* Sequencing analysis of the Human Immunodeficient virus (HIV-1) and HCMV

RESEARCH SKILLS

* Pre- PCR handling and processing of clinical specimens for

diagnosis-(Cerebrospinal Fluid, Amniotic Fluid, Plasma and Fine

needle aspirations of Human Breast and Head and Neck tumor

biopsies

* RNA and DNA extraction from Plasma and infected cells in tissue

culture.

* PCR

- Qualitative RT-PCR

- Quantitative RT-PCR

- Analytical PCR.

* Analysis of PCR products

- Radioactive probe kinasing

- Liquid Hybridization

- Poly-acrylamide and agarose gel electrophoresis

- Analysis and quantitation using Phosphor-Imager.

* Branched DNA assay

* Molecular Cloning

- TA cloning, Restriction Endonuclease Digestion, Ligation, Transforma-

tion, RNA\DNA fragment purification, Plasmid preparation.

* Nucleic Acid Sequencing, computer analysis.

* Proteomics

- Immunoprecipitations

- Westerns

- In vitro translation

* Elisa Assays

* Tissue Culture

- Cell based assays to determine (Sensitization to anti-tumor agents,

cytostatic/cytotoxic effects, Duration effect, Accumulation assays).

- Co-transfection assays

(luciferace, and Beta-gal. reporter assays)

- Membrane preparations

- Photoaffinity Radio-labeling assay

- HCMV viral infection and titration

- Maintenance of various cancer cell lines.

- Morphometry and computer analysis

- Flow Cytometry

* Animal handling

- Aseptic Surgery

- Dosing (i.v. i.p. oral)

* Data analysis, entry and preparation of complete report using

computer.

* Data presentation and discussion at seminars and laboratory group

meetings

* Assist in write-up of data for publication.

* General laboratory maintenance.

OTHER WORK EXPERIENCE

* Helped establish and run family owned business

- Import/export leather goods

- Pizzeria restaurant

- Super market

Language Skills: Fluency in English, French, and Arabic.

PUBLICATIONS

* LGD-5552, an anti-inflammatory glucocorticoid receptor ligand with reduced side effects, in

vivo.

López FJ, Ardecky RJ, Bebo B, Benbatoul K, De Grandpre L, Liu S, Leibowitz MD,

Marschke K, Rosen J, Rungta D, Viveros HO, Yen WC, Zhi L, Negro-Vilar A, Miner JN.

Endocrinology. 2008 May;149(5):2080-9. Epub 2008 Jan 24.

* Anti-inflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered

protein-protein interaction profile.

Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, Marschke K, Rosen J,

Vajda E, Zhi L, Negro-Vilar A.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. Epub 2007 Nov 21.

* Identification of a potent and rapidly reversible inhibitor of the 20S-proteasome.

Purandare AV, Wan H, Laing N, Benbatoul K, Vaccaro W, Poss MA.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4701-4.

* 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug

resistance. Part 2.

Zhang C, Sarshar S, Moran EJ, Krane S, Rodarte JC, Benbatoul KD, Dixon R, Mjalli AM.

Bioorg Med Chem Lett. 2000 Dec 4;10(23):2603-5.

* 2,4,5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug

resistance. Part 1.

Sarshar S, Zhang C, Moran EJ, Krane S, Rodarte JC, Benbatoul KD, Dixon R, Mjalli AM.

Bioorg Med Chem Lett. 2000 Dec 4;10(23):2599-601.

* Discovery and characterization of OC144-093, a novel inhibitor of P- glycoprotein-mediated

multidrug resistance.

Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT,

Dixon R, Guns ES, Mayer LD.

Cancer Res. 2000 Jun 1;60(11):2964-72.

* Increase in tumor GADD153 mRNA level following treatment correlates with response to pacli

taxel.

de las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, D'Agostino

HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los

Cancer Chemother Pharmacol. 2000;45(5):381-8.

* Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor

response in head and neck cancer.

Los G, Benbatoul K, Gately DP, Barton R, Christen R, Robbins KT, Vicario D, Kirmani S,

Orloff LA, Weisman R, Howell SB.

Clin Cancer Res. 1999 Jul;5(7):1610-8.

* Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast.

Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A, Green M, Newsham

Oncogene. 1998 Dec 31;17(26):3499-505.

* Quantitation of Gene Expression in Human Tumor Biopsies by RT-PCR Using the Molecular

Imager Storage Phosphor Imaging System

Benbatoul Khalid, Onoda Naoyoshi, Los Gerrit.

Bio-Rad Technical Jouranl US/EG Bulletin 2011

ABSTRACTS

* Efficient target delivery of protein toxins using self –manufacturing nanoparticles (minicells) de-

livered from bacteria. Biosynthesis and characterization of targeted nanotoxins (TNT).

Vaxiion 2012 AACR poster #5703, Chicago

Michael J. Newman, Khalid Benbatoul, Brian Hancock, Veronica Hernandez, Shingo Tsuji,

Jacques Weissman, Matthew J. Giacalone .

* Molecular mechanism of selective regulation of gene expression by the selective Glucocorticoid

Receptor Modulator, LGD5552.

Endocrine Society meeting, San Diego

Jeffrey N Miner*, Robert Ardecky, Khalid Benbatoul, William Chang, Sha Liu,

Francisco Lopez, Keith Marschke, Jonathan Rosen, Eric Vajda, O. Humberto

Viveros, Peter Vollmayr, Lin Zhi and Andres Negro-Vilar.

* Development of the Golden Syrian Hamster as an in vivo model to investigate chemotherapy

induced alopecia.

Bristol Myers Squibb poster symposia.

Khalid Benbatoul, Naomi Laing, Kevin Webster.

* Cisplatin-induced cellular injury response monitored by gadd153 expression.

4th Int. Conference on Head and Neck cancer, Toronto, Canada 1996.

Los G, Weisman R, Weiner D, Benbatoul K, Barton R, Robbins KT, Howell SB.

* Identification of markers reflecting the extent of injury induced in human tumors

following treatment with chemotherapeutic agents.

Proc. Am. Ass Cancer Res. 37: 1996.

Los G, Weisman R, Weiner D, Benbatoul K, Van Veelen L, Barton R,

De las Alas M, Christen R, Kirmani S, Robbins KT, Howell SB.

* Loss of wild-type p53 does not affect the emergence of cisplatin resistance in

RKO colorectal carcinoma cell lines.

Proc. 7th International Symposium on platinum and other metal coordination compounds in cancer

chemotherapy, 7: 178, 1995.

Los G, Wielders CLC, Tuyt L, Benbatoul K, Howell SB.

* Emergence of cisplatin (cDDP) resistance is not effected by p53.

Proc. Am. Ass. Cancer Res. 36: 12, 1995.

Wielders CLC, Tuyt L, Benbatoul K, Barton R, Howell SB, Los G.

* Modulation of drug cytotoxicity and apoptosis by nicotine.

Proc. Am. Ass. Cancer Res. 36: 13, 1995.

Onoda N, Symons K, Benbatoul K, Najafian H, Howell SB, Los G.

* Molecular Characterization of Foscarnet Resistant Phenotypes of Viral Isolates

from HCMV Retinitis Patients. Submitted May-1994

Irene L. Smith, Benbatoul K, Jiles R. E, Minor R, Drew L, S.A. Spector.

Contact this candidate